BioNTech SE (WBO:BNTX) Long-Term Debt : €191 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is BioNTech SE Long-Term Debt?

BioNTech SE's Long-Term Debt for the quarter that ended in Dec. 2023 was €191 Mil.

BioNTech SE's quarterly Long-Term Debt declined from Jun. 2023 (€167 Mil) to Sep. 2023 (€162 Mil) but then increased from Sep. 2023 (€162 Mil) to Dec. 2023 (€191 Mil).

BioNTech SE's annual Long-Term Debt increased from Dec. 2021 (€172 Mil) to Dec. 2022 (€176 Mil) and increased from Dec. 2022 (€176 Mil) to Dec. 2023 (€191 Mil).

BioNTech SE Long-Term Debt Historical Data

The historical data trend for BioNTech SE's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Long-Term Debt Chart

BioNTech SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

231.00

171.60

176.20

191.00

BioNTech SE Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Debt	Get a 7-Day Free Trial															176.20	172.40	167.10	161.90	191.00

BioNTech SE (WBO:BNTX) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

BioNTech SE Long-Term Debt Related Terms

Thank you for viewing the detailed overview of BioNTech SE's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNTech SE (WBO:BNTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (WBO:BNTX) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

BNTX:USA BNTX:Mexico 0A3M:UK 22UA:Germany B1NT34:Brazil

Address

An der Goldgrube 12, Mainz, RP, DEU, D-55131

Website

https://www.biontech.de

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.